Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them?

Navarro A, Martinez-Marti A, Felip E.

J Thorac Oncol. 2018 Jul;13(7):874-876. doi: 10.1016/j.jtho.2018.05.005. No abstract available.

PMID:
29935842
2.

A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.

Giaccone G, Sanborn RE, Waqar SN, Martinez-Marti A, Ponce S, Zhen H, Kennealey G, Erickson-Viitanen S, Schaefer E.

Clin Lung Cancer. 2018 Mar 23. pii: S1525-7304(18)30058-5. doi: 10.1016/j.cllc.2018.03.016. [Epub ahead of print]

PMID:
29681434
3.

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.

Cedrés S, Felip E, Cruz C, Martinez de Castro A, Pardo N, Navarro A, Martinez-Marti A, Remon J, Zeron-Medina J, Balmaña J, Llop-Guevara A, Miquel JM, Sansano I, Nuciforo P, Mancuso F, Serra V, Vivancos A.

J Natl Cancer Inst. 2018 Feb 26. doi: 10.1093/jnci/djy012. [Epub ahead of print]

PMID:
29529211
4.

Corrigendum to "Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches" [Lung Cancer 106 (2017) 70-75].

Remon J, Pardo N, Martinez-Martí A, Cedrés S, Navarro A, Martinez de Castro AM, Felip E.

Lung Cancer. 2018 Mar;117:80. doi: 10.1016/j.lungcan.2017.11.007. Epub 2018 Feb 3. No abstract available.

PMID:
29398170
5.

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).

Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel JM, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer HG, Vivancos A.

Ann Oncol. 2017 Oct 1;28(10):2451-2457. doi: 10.1093/annonc/mdx396.

PMID:
28961841
6.

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.

Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, Navarro A, Condom E, Moran S, Gomez-Lopez G, Graña O, Rubio-Camarillo M, Martinez-Martí A, Yokota J, Carretero J, Galbis JM, Nadal E, Pisano D, Sozzi G, Felip E, Montuenga LM, Roz L, Villanueva A, Sanchez-Cespedes M.

Clin Cancer Res. 2017 Jun 15;23(12):3203-3213. doi: 10.1158/1078-0432.CCR-16-1946. Epub 2017 Mar 16.

7.

Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.

Remon J, Pardo N, Martinez-Martí A, Cedrés S, Navarro A, Martinez de Castro AM, Felip E.

Lung Cancer. 2017 Apr;106:70-75. doi: 10.1016/j.lungcan.2017.02.002. Epub 2017 Feb 6. Review. Erratum in: Lung Cancer. 2018 Feb 1;:.

PMID:
28285697
8.

Single-cell transcriptome conservation in cryopreserved cells and tissues.

Guillaumet-Adkins A, Rodríguez-Esteban G, Mereu E, Mendez-Lago M, Jaitin DA, Villanueva A, Vidal A, Martinez-Marti A, Felip E, Vivancos A, Keren-Shaul H, Heath S, Gut M, Amit I, Gut I, Heyn H.

Genome Biol. 2017 Mar 1;18(1):45. doi: 10.1186/s13059-017-1171-9.

9.

Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

Cedrés S, Ponce-Aix S, Pardo-Aranda N, Navarro-Mendivil A, Martinez-Marti A, Zugazagoitia J, Sansano I, Montoro MA, Enguita A, Felip E.

Lung Cancer. 2016 Jun;96:1-6. doi: 10.1016/j.lungcan.2016.03.001. Epub 2016 Mar 10.

PMID:
27133741
10.

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E.

PLoS One. 2015 Mar 16;10(3):e0121071. doi: 10.1371/journal.pone.0121071. eCollection 2015.

11.

Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate?

Martinez P, Martinez-Marti A, Navarro A, Cedrés S, Felip E.

Lung Cancer. 2014 May;84(2):97-100. doi: 10.1016/j.lungcan.2014.01.018. Epub 2014 Jan 30. Review.

PMID:
24582269
12.

Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients.

Martinez P, Hernández-Losa J, Montero MÁ, Cedrés S, Castellví J, Martinez-Marti A, Tallada N, Murtra-Garrell N, Navarro-Mendivill A, Rodriguez-Freixinos V, Canela M, Ramon y Cajal S, Felip E.

PLoS One. 2013;8(1):e52261. doi: 10.1371/journal.pone.0052261. Epub 2013 Jan 24.

13.

Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments.

Felip E, Martinez-Marti A, Martinez P, Cedres S, Navarro A.

Curr Opin Oncol. 2013 Mar;25(2):115-20. doi: 10.1097/CCO.0b013e32835ca1b0. Review.

PMID:
23262832
14.

DNA repair protein expression in resected NSCLC: a different predictive value for platinum benefit in adenocarcinoma versus squamous-cell carcinoma?

Felip E, Martinez-Marti A.

Ann Oncol. 2012 Sep;23(9):2211-4. doi: 10.1093/annonc/mds157. Epub 2012 Jun 8. No abstract available.

PMID:
22684743
15.

PI3K Pathway in NSCLC.

Martinez-Martí A, Felip E.

Front Oncol. 2012 Jan 6;1:55. doi: 10.3389/fonc.2011.00055. eCollection 2011.

Supplemental Content

Loading ...
Support Center